Skip to content
metaboliq

Tirzepatide: how it works, what it is approved for in India, and side effects

Tirzepatide acts on two gut hormone receptors, GIP and GLP-1. In India it is sold as Mounjaro and Yurpeak and is approved for adults with type 2 diabetes and for chronic weight management in adults. It is prescription-only, and a doctor decides whether it fits you.

Brands in India
Mounjaro (Eli Lilly) and Yurpeak (Cipla).
Approved in India for
Type 2 diabetes in adults; chronic weight management in adults.
How it is taken
Once a week, under the skin, from a pen.
Who decides
A doctor, after your history and blood tests.

How tirzepatide works

Tirzepatide is one molecule that acts on two receptors: GIP and GLP-1, both for hormones the gut releases after a meal. It slows how fast the stomach empties, increases fullness, reduces appetite and helps the body handle blood sugar.

Sources: [1]

What the trials found

In SURMOUNT-1, adults without diabetes reduced body weight by an average of 15.0%, 19.5% and 20.9% on the 5, 10 and 15 mg strengths over 72 weeks, against 3.1% on placebo.

Head to head in SURMOUNT-5, average reduction over 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide 2.4 mg.

Sources: [2], [3]

Who it is approved for in India

Approved in India for adults with type 2 diabetes, and for chronic weight management in adults with obesity, or with overweight and a related condition.

Mounjaro and Yurpeak are the same tirzepatide; Cipla sells Yurpeak under an arrangement with Lilly.

Sources: [4], [5], [7]

Who decides, and how it is started

It is prescription-only in India, and a doctor decides whether it fits you after reading your history, your blood tests and anything else you take.

It is started at a low strength and stepped up every four weeks or so, because stepping up slowly is what keeps the stomach side effects manageable.

Sold outside an authorised pharmacy, a pen can be fake, wrongly stored or the wrong strength; the regulator has asked states to keep these products to authorised channels and their approved uses.

Sources: [7]

What it costs in India

Reported figures put tirzepatide pens in India at about Rs 13,125 to Rs 25,781 a month, rising with the strength. These are reported market prices, they change, and a pharmacist quotes the current MRP.

Sources: [6]

Why muscle matters

Body weight falls as fat and as lean tissue together. In the STEP 1 body-composition substudy, roughly 40% of the total lost was lean mass.

Muscle is what keeps blood sugar handled well, keeps you strong as you age and keeps your daily energy use up. So the plan around any treatment protects it: protein at every meal, strength training two or three times a week, and body composition measured rather than the scale alone.

Sources: [8]

What happens when it is stopped

These work while they are taken. One year after semaglutide was stopped in the STEP 1 extension, people had regained about two-thirds of what they had lost; in SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight.

That is why the habits built alongside treatment, and a plan for maintenance, matter as much as the treatment itself.

Sources: [9], [10]

Side effects

Common, and usually easing with time

  • Nausea, most often in the first weeks and after each step up.
  • Diarrhoea or constipation.
  • Vomiting, indigestion, burping and bloating.
  • Feeling full early, and less appetite.
  • Tiredness, and headache.

Serious, and rare

  • Pancreatitis: severe, lasting pain in the upper abdomen that may spread to the back, with or without vomiting.
  • Gallbladder problems, including gallstones, which are more likely when body weight falls quickly.
  • Dehydration from vomiting or diarrhoea, which can strain the kidneys.
  • Low blood sugar, mainly when it is combined with insulin or a sulfonylurea.
  • Allergic reactions, rare but serious.
  • A history of medullary thyroid cancer or MEN 2 in you or your family is a reason it is not used.

Stop and get medical help at once for severe abdominal pain, repeated vomiting, signs of an allergic reaction, or sudden changes in vision. Tell the doctor about pregnancy plans first: these are not used in pregnancy.

Questions people ask

Is tirzepatide better than semaglutide?

In the one head-to-head trial, SURMOUNT-5, average reduction in body weight was larger with tirzepatide. Which suits a person is a doctor's call, made on their history, tests and tolerance.

What brands of tirzepatide are sold in India?

Mounjaro, from Eli Lilly, and Yurpeak, from Cipla. They are the same molecule.

Does tirzepatide affect the contraceptive pill?

It can make tablets taken by mouth less reliable for a few weeks after starting and after each step up. The label advises adding a barrier method for four weeks at those times; ask the doctor.

Every source, in full

  1. [1] Mounjaro: EPAR and product information

    European Medicines Agency, 2025. The full label: approved uses, how it is started and stepped up, warnings, and the side effects seen in trials with how often each occurred.

    Read the source
  2. [2] Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    New England Journal of Medicine, 2022. Adults without diabetes on tirzepatide 5, 10 or 15 mg, with diet and activity, reduced body weight by an average of 15.0%, 19.5% and 20.9% over 72 weeks, against 3.1% on placebo.

    Read the source
  3. [3] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)

    New England Journal of Medicine, 2025. Head to head over 72 weeks, average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide 2.4 mg.

    Read the source
  4. [4] Eli Lilly launches Mounjaro in India

    DD News, 2025. Lilly launched Mounjaro in India after approval from the national regulator, for type 2 diabetes and for chronic weight management in adults.

    Read the source
  5. [5] Cipla launches Yurpeak (tirzepatide)

    Cipla press release, 2025. Cipla launched Yurpeak, the same tirzepatide as Mounjaro, in India under an arrangement with Lilly.

    Read the source
  6. [6] Yurpeak cost in India

    drrajatgoel.com, 2026. Reports a monthly cost for tirzepatide pens in India of about Rs 13,125 to Rs 25,781, rising with the strength.

    Read the source
  7. [7] DCGI letter to states on the sale and promotion of GLP-1 receptor agonists, 27 March 2026

    Central Drugs Standard Control Organisation, via Medical Dialogues, 2026. Directs states to ensure these products are sold only through authorised channels, strictly in line with their approved indications and labelling.

    Read the source
  8. [8] Body composition changes with semaglutide in the STEP 1 body-composition substudy, reviewed

    Postgraduate Medicine, 2022. In the STEP 1 body-composition substudy, roughly 40% of the total body weight lost was lean mass rather than fat.

    Read the source
  9. [9] Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

    Diabetes, Obesity and Metabolism, 2022. One year after semaglutide was stopped, participants had regained about two-thirds of the body weight they had lost.

    Read the source
  10. [10] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)

    JAMA, 2024. After 36 weeks on tirzepatide, people switched to placebo regained about 14% of body weight by week 88; people who continued went on to a further 5.5% reduction.

    Read the source

Talk to a doctor about your own results.

A registered doctor reads your blood report and your history, and decides with you what comes next.